wer möchte auf Geld verdien verzichten

weiß nicht so recht was ich von Caly glauben sollllllllllll.
 

mir geht´s ganz gut, außer die Hitze im Büro... Du meinst sicherlich Viragen anstatt Caly, oder? Viragen geht mir grad etwas auf´m Hammer, kaum Umsatz, dieses rumgedümpel, naja, warten wir einfach mal ab, ich verkaufe jedenfalls nicht mit Verlusten. Hast Du noch Deine VRA-Papiere?  

ich gehe jetzt Jetski fahren hab die schnauze voll vom Büro etc...

MFG
TB  

sag mal, musst nicht arbeiten, oder lebst Du nur von der Börse? Ich kann leider nicht einfach so JetSki fahren (na gut, in Stuttgart macht sich das vielleicht auch nicht so gut, höchstens auf´m Necker). Wohnst Du an der Nord- oder Ostsee?  

Aktueller Kurs in USA 0,32$
Keine markante Absicherung durch Bids nach unten!

Der Weg nach unten ist quasi frei...  

scheiß Viragen-Aktie, die kotzt mich grad an!  

Info zu Viragen? Das perplexe an den BioTech´s ist ja immer, dass sobald eine gute AdHoc kommt, der Kurs nach oben schnellt, aber fundamental keine Bodenbildung entsteht.  

ich fahre in der Nordsee.
Viragen kommt wird wohl bald wieder steigen  

VIRAGEN CONTINUES TO MEET AMERICAN STOCK EXCHANGE LISTING CRITERIA
Company To Amend SEC Filing Which States Otherwise

PLANTATION, FLORIDA - May 30, 2003 - Viragen, Inc. (AMEX: "VRA") today corrected erroneous information contained in a preliminary prospectus included in a Form S3 that the Company filed with the Securities and Exchange Commission (SEC) this morning.

The filing incorrectly states that, "We (Viragen) do not currently meet minimum bid price requirements of the American Stock Exchange (AMEX), and if we are delisted from the American Stock Exchange, the trading market for our common stock could be eliminated." Viragen currently meets AMEX maintenance criteria and is considered in good standing. The Company has no reason to believe that it is a candidate for possible delisting. The Company will immediately amend its Form S3 and file the corrected document with the SEC.

About Viragen, Inc.
Viragen is a biotechnology company specializing in the research, development and commercialization of natural and recombinant protein-based drugs designed to treat a broad range of viral and malignant diseases. These protein-based drugs include natural human alpha interferon, monoclonal antibodies, peptide drugs and therapeutic vaccines. Viragen's strategy also includes the development of Avian Transgenic Technology for the large-scale, cost-effective manufacturing of its portfolio of protein-based drugs, as well as offering Contract Manufacturing for the entire biopharmaceutical industry.

Viragen is publicly traded on the American Stock Exchange (VRA). Viragen's majority owned subsidiary, Viragen International, Inc., is publicly traded on the Over-The-Counter Bulletin Board (VGNI). Viragen's key partners and licensors include: Roslin Institute, Memorial Sloan-Kettering Cancer Center, National Institutes of Health, Cancer Research UK, University of Nottingham (U.K.), University of Miami, America's Blood Centers and the German Red Cross.


--------------------------------------------------

Viragen, Inc. Corporate Contact:

Douglas Calder, Director of Communications
Phone: (954) 233-8746; Fax: (954) 233-1414
E-mail: dcalder@viragen.com


--------------------------------------------------

The foregoing press release contains forward-looking statements that can be identified by such terminology such as "expects", "potential", "suggests", "may", "will", or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the Company's ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.


--------------------------------------------------

Click HERE for previous press release.


Copyright © 2003  

 

also ca. 0,316 €... die kommt schon wieder!

VRA ist nichts für schwache Nerven. Aber nachdem die "Ente" mit dem anstehenden "Delisting" dementiert wurde wirds wieder hochgehen.
Habe den Kursrückschlag genutzt um mich wieder einzudecken! ;-)
 

wie meinst Du das genau mit dem Delisting?  

Siehe Posting Nr.109 von Tamer

"The filing incorrectly states that, "We (Viragen) do not currently meet minimum bid price requirements of the American Stock Exchange (AMEX), and if we are delisted from the American Stock Exchange, the trading market for our common stock could be eliminated." Viragen currently meets AMEX maintenance criteria and is considered in good standing. The Company has no reason to believe that it is a candidate for possible delisting. The Company will immediately amend its Form S3 and file the corrected document with the SEC."

Ich meinte, dass die Falschmeldung hiermit dementiert wurde.

 

 

 

die Aktie nicht arg zu beflügeln, eher Richtung Süden. Was ist denn da los?  

 

ich weder nochmals nachlegen alle sterne stehen gut.
Neue Nachrichten sind positiv, wird wohl  um einige hundert Prozent steigen in den nächsten wochen.



Mfg an alleeeeeeeeeeeeeeeeeeeeeeeeeeeeeee  

?  

 

ANNOUNCEMENT - Notice of Special Meeting of StockholdersINVESTOR RELATIONS CONTACT:

Communications

Douglas Calder,
Director of Communications

(954) 233-8746 - Fax (954) 233-1414

E-mail: dcalder@viragen.com


--------------------------------------------------

Viragen will hold a special meeting of stockholders at the Renaissance Plantation Hotel located at 1230 Pine Island Road, Plantation, Florida, on Wednesday, June 25, 2003 at 2:00 p.m. (EDT)

Stockholders of record at the close of business May 27, 2003 will be entitled to vote at the meeting or by proxy to authorize certain equity financings as well as to approve a proposal to increase the number of authorized shares from 250 million to 700 million.

A copy of the proxy statement is being mailed to stockholders on or about May 30, 2003.  Stockholders are urged to read the proxy statement because it contains important information.  Stockholders and investors may obtain a free copy of the proxy statement and other Company filings and documents by directly contacting the Company, by clicking the provided link or by accessing the SEC's website at http://www.sec.gov.

Click HERE for copy of proxy in .PDF format    

"The Board has determined that the approval of these measures would provide Viragen the flexibility to execute its long-range business plan.  Subject to approval by the stockholders, the Company will have access to our recently announced $12 million equity line of credit, subject to SEC clearance," stated Viragen's Chairman, Mr. Carl Singer.  "We intend to draw upon the equity line as needed to fund our operations and progress our commercial and scientific programs.  Our intent is to minimize the use of authorized but unissued shares, but we have based our request for the increased authorization on a set of assumptions which provides for unexpected events and/or opportunities.  While the equity line will provide the needed funding, we will continue to seek strategic partners and new investors which could reduce the number of equity transactions needed to fund operations. Growth and expansion of our commercial activities could also diminish our reliance upon equity transactions to fund our business plan. In addition, management continues to aggressively contain costs, direct resources to priority programs and work towards building stockholder value.  We appreciate our stockholders' continued support."
 

 

 

 

bin wieder da, hab´s mir eine Woche in Kalabrien gut gehen lassen. Wie steht´s mit Viragen? Konnte sich noch nicht richtig konsolidieren, oder? Die Umsätze lassen auch
zu wünschen übrig, da bleibt nur die Möglichkeit abzuwarten...  

:-((